Biomarker Research for Moyamoya Disease in Cerebrospinal Fluid Using Surface-enhanced Laser Desorption/Ionization Time-of-flight Mass Spectrometry

Moyamoya disease (MMD) is a rare cerebrovascular disease characterized by steno-occlusive change in bilateral internal carotid arteries with unknown etiology. To discover biomarker candidates in cerebrospinal fluid from MMD patients, proteome analysis was performed by the surface-enhanced laser deso...

Full description

Saved in:
Bibliographic Details
Published in:Journal of stroke and cerebrovascular diseases 2015-01, Vol.24 (1), p.104-111
Main Authors: Maruwaka, Mikio, MD, Yoshikawa, Kazuhiro, PhD, Okamoto, Sho, PhD, Araki, Yoshio, PhD, Sumitomo, Masaki, MD, Kawamura, Akino, MD, Yokoyama, Kinya, MD, Wakabayashi, Toshihiko, PhD
Format: Article
Language:English
Subjects:
Adolescent
Adult
angiogenesis
biomarker
Biomarkers - cerebrospinal fluid
Cardiovascular
cerebrospinal fluid (CSF)
Child
Child, Preschool
Female
Humans
Infant
Magnetic Resonance Imaging
Male
Middle Aged
Moyamoya disease (MMD)
Moyamoya Disease - cerebrospinal fluid
Moyamoya Disease - pathology
Neovascularization, Pathologic - pathology
Neurology
Pilot Projects
Proteomics - methods
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization - methods
surface-enhanced laser desorption/ionization mass spectrometry (SELDI-TOF-MS)
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Moyamoya disease (MMD) is a rare cerebrovascular disease characterized by steno-occlusive change in bilateral internal carotid arteries with unknown etiology. To discover biomarker candidates in cerebrospinal fluid from MMD patients, proteome analysis was performed by the surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. Three peptides, 4473Da, 4475Da, and 6253Da, were significantly elevated in MMD group. A positive correlation between 4473Da peptide and postoperative angiogenesis was determined. Twenty MMD patients were enrolled in this pilot study, including 11 pediatric cases less than 18 years of age (mean age, 8.67 years) and 9 adult MMD patients (mean age, 38.1 years). This study also includes 17 control cases with the mean age of 27.9 years old. In conclusion, 4473Da peptide is supposed to be a reliable biomarker of MMD. 4473Da peptide showed higher intensity peaks especially in younger MMD patients, and it was proved to be highly related to postoperative angiogenesis. Further study is needed to show how 4473Da peptide is involved with the etiology and the onset of MMD.
ISSN:1052-3057
1532-8511
DOI:10.1016/j.jstrokecerebrovasdis.2014.07.028